The biopharmaceutical industry is entering 2026 with a noticeably different posture than in the speculative, narrative-driven years that preceded it. Across public and private markets, investors appear to be treating 2026 as a “clearing year”—a period when long-promised breakthroughs in novel therapeutic modalities and AI-driven discovery face sharper scrutiny from pivotal clinical trials, real-world tolerability, … [Illustrations] 2026 Biopharma’s “Clearing Year”: IRA, BIOSECURE, and the Phase 3 Threshold Becoming the True Litmus Test Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.